Danielle Brill

Stock Analyst at Truist Securities

(3.79)
# 733
Out of 5,044 analysts
88
Total ratings
43.42%
Success rate
12.31%
Average return

Stocks Rated by Danielle Brill

Alnylam Pharmaceuticals
Oct 17, 2025
Maintains: Buy
Price Target: $459$535
Current: $481.59
Upside: +11.09%
Immunovant
Oct 14, 2025
Initiates: Hold
Price Target: $16
Current: $21.65
Upside: -26.10%
Upstream Bio
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $24.19
Upside: +94.30%
Dianthus Therapeutics
Oct 14, 2025
Initiates: Buy
Price Target: $56
Current: $33.82
Upside: +65.58%
Palvella Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $56$80
Current: $75.17
Upside: +6.43%
Vertex Pharmaceuticals
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $417.21
Upside: -
Disc Medicine
Jul 21, 2025
Initiates: Buy
Price Target: $86
Current: $85.00
Upside: +1.18%
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $29.32
Upside: +63.71%
Tectonic Therapeutic
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $18.62
Upside: +243.72%
Neurocrine Biosciences
Jul 21, 2025
Initiates: Buy
Price Target: $163
Current: $138.02
Upside: +18.10%
Initiates: Buy
Price Target: $66
Current: $66.62
Upside: -0.93%
Initiates: Buy
Price Target: $30
Current: $23.98
Upside: +25.10%
Initiates: Buy
Price Target: $24
Current: $18.85
Upside: +27.32%
Upgrades: Strong Buy
Price Target: $20$52
Current: $70.59
Upside: -26.34%
Reinstates: Market Perform
Price Target: n/a
Current: $16.25
Upside: -
Reinstates: Outperform
Price Target: $79
Current: $51.86
Upside: +52.33%
Reinstates: Outperform
Price Target: $18
Current: $12.84
Upside: +40.19%
Reinstates: Outperform
Price Target: $150
Current: $23.45
Upside: +539.66%
Reinstates: Market Perform
Price Target: n/a
Current: $147.86
Upside: -
Reinstates: Strong Buy
Price Target: $605
Current: $821.97
Upside: -26.40%
Reinstates: Market Perform
Price Target: n/a
Current: $22.53
Upside: -
Reinstates: Outperform
Price Target: $50
Current: $42.30
Upside: +18.20%
Reinstates: Outperform
Price Target: $51
Current: $41.96
Upside: +21.54%
Maintains: Outperform
Price Target: $180$100
Current: $7.43
Upside: +1,245.90%
Downgrades: Underperform
Price Target: n/a
Current: $67.35
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $10.91
Upside: -